权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Kidney Injury by Cisplatin and Renoprotective Strategies.

顺铂引起的肾损伤和肾脏保护策略。

基本信息

批准号：
10579273
负责人：
Zheng Dong
金额：
$ 41.84万
依托单位：
AUGUSTA UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-09-30 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10579273
关键词：
Acute Acute Renal Failure with Renal Papillary Necrosis Animal Model Animals Antineoplastic Agents Autophagocytosis Autophagosome Cancer Patient Cell physiology Cells Chronic Chronic Kidney Failure Cisplatin Conditioned Culture Media Cytoplasm Development Dose Fibroblasts Fibrosis Goals Injury Injury to Kidney Kidney Knockout Mice Long-Term Effects Longitudinal Studies Modeling Mus Normal tissue morphology Organ Pathogenesis Pathology Pharmaceutical Preparations Phenotype Positioning Attribute Production Profibrotic signal Regulation Renal tubule structure Reporting Research Role TP53 gene Testing Tubular formation Work cancer therapy chemotherapy fibrogenesis hypoxia inducible factor 1 inhibition of autophagy inhibitor insight interstitial kidney fibrosis knockout gene long-term sequelae mouse model nephrotoxicity new therapeutic target novel strategies pharmacologic prevent side effect tool tumor

项目摘要

Project Summary The goal of this project is to investigate the long-term sequelae of cisplatin chemotherapy in kidneys. Cisplatin is one of the most widely used and most potent cancer therapy drugs. However, cisplatin chemotherapy is frequently associated with adverse side-effects in kidneys, resulting in acute kidney injury and chronic kidney problems. While the past work has focused on acute kidney injury by cisplatin, very little is known about the chronic or long-term effect of cisplatin treatment in kidneys. A major hurdle in studying the long-term effect of cisplatin is the lack of appropriate animal models. But we and others have recently established the mouse model of repeated low dose cisplatin treatment that leads to renal fibrosis and chronic kidney disease, opening the door to the research of the long-term sequelae of cisplatin chemotherapy in kidneys. Using this model, the current application will investigate autophagy in renal fibrosis and chronic kidney disease following cisplatin treatment. The application is supported by critical preliminary findings: (1) Following cisplatin treatment, autophagy is induced along with the development of chronic kidney pathologies including renal fibrosis; (2) Autophagy inhibitors given after cisplatin treatment can prevent the development of chronic kidney problems; (3) Renal tubular cells may produce and secret specific profibrotic factors in an autophagy-dependent manner; and (4) At the upstream, cisplatin treatment leads to the activation of p53 and hypoxia-inducible factor-1 (HIF-1), two potential regulators of autophagy. Based on these findings, we hypothesize that: Cisplatin treatment leads to the activation of p53 and HIF-1, which induce persistent autophagy in renal tubular cells. Persistent autophagy then triggers a secretory phenotype in these tubular cells for the production and secretion of profibrotic factors, which activate interstitial fibroblasts to promote renal fibrosis and the progression to CKD. We will test this hypothesis by three Specific Aims: (1) test the hypothesis that blockade of autophagy may ameliorate renal fibrosis and CKD following cisplatin treatment, while enhancing chemotherapy in tumors; (2) test the hypothesis that p53 and/or HIF-1 contribute to autophagy activation, renal fibrosis and CKD following cisplatin treatment; and (3) test the hypothesis that renal tubular cells produce profibrotic factors in an autophagy-dependent manner for fibroblast activation and fibrogenesis. Completion of the research will gain significant new insights into the long- term side-effects of cisplatin treatment in kidneys. Moreover, by targeting autophagy and HIF-1, the work may identify novel strategies that not only protect kidneys in cisplatin treatment but also enhance chemotherapy in tumors.

项目摘要本研究的目的是探讨肾脏顺铂化疗的长期后遗症。顺铂是目前应用最广泛、最有效的肿瘤治疗药物之一。然而，顺铂化疗通常与肾脏中的不良副作用相关，导致急性肾功能衰竭。损伤和慢性肾脏问题。虽然过去的工作集中在顺铂引起的急性肾损伤，关于顺铂治疗在肾脏中的慢性或长期作用知之甚少。一个主要障碍在研究顺铂的长期作用方面缺乏合适的动物模型。但我们和其他人最近建立了重复低剂量顺铂治疗的小鼠模型，纤维化和慢性肾脏疾病，打开大门的长期后遗症的研究，肾脏顺铂化疗。利用这个模型，目前的应用将调查自噬肾纤维化和慢性肾脏疾病顺铂治疗。应用程序支持关键的初步发现：（1）顺铂治疗后，自噬沿着慢性肾脏病理的发展，包括肾纤维化;（2）自噬抑制剂，顺铂治疗可以预防慢性肾脏问题的发展;（3）肾小管细胞可能以自噬依赖的方式产生和分泌特定的促纤维化因子;和（4）在在上游，顺铂治疗导致p53和缺氧诱导因子-1（HIF-1）的激活，自噬的潜在调节剂基于这些发现，我们假设：顺铂治疗导致p53和HIF-1的活化，其诱导肾小管细胞中的持续自噬。持续的自噬然后触发这些肾小管细胞中的分泌表型，用于产生和促纤维化因子的分泌，其激活间质成纤维细胞以促进肾纤维化，进展为CKD。我们将通过三个具体目标来检验这一假设：（1）检验以下假设：阻断自噬可以改善顺铂治疗后的肾纤维化和CKD，增强肿瘤的化疗;（2）检验p53和/或HIF-1有助于肿瘤发生的假设。顺铂治疗后自噬激活、肾纤维化和CKD;和（3）检验假设肾小管细胞对成纤维细胞以自噬依赖的方式产生促纤维化因子活化和纤维形成。完成这项研究将获得重要的新见解，长期- 顺铂治疗对肾脏的长期副作用。此外，通过靶向自噬和HIF-1，这项工作可能会发现新的策略，不仅在顺铂治疗中保护肾脏，肿瘤的化疗